{
  "PEB.NZ": {
    "city": "Dunedin",
    "country": "New Zealand",
    "currency": "NZD",
    "exchange": "NZE",
    "industry": "Diagnostics & Research",
    "long_name": "Pacific Edge Limited",
    "market": "nz_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Pacific Edge Limited Ordinary S",
    "state": null,
    "summary": "Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; and Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers, which are in clinical and user trials. In addition, the company is developing products for gastric, melanoma, and endometrial cancers, which are in pre-clinical trials. Pacific Edge Limited was founded in 2001 and is headquartered in Dunedin, New Zealand.",
    "website": "http://www.pacificedgedx.com",
    "zipcode": "9016"
  }
}
